AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

AbbVie (ABBV) has been a trending stock, returning +5.1% over the past month, outperforming the S&P 500 but lagging its large-cap pharmaceutical peers. The company is projected for strong financial performance, with current quarter EPS expected to rise 9% to $3.27 and full-year revenue forecasts indicating a 7.6% increase to $60.63 billion. ABBV has consistently beaten consensus revenue and EPS estimates over the last four quarters. Despite these robust growth projections and recent beats, the stock holds a Zacks Rank #3 (Hold) and a 'C' valuation grade, suggesting it may perform in line with the broader market in the near term and trades at par with its industry peers.

Analysis

AbbVie's recent stock performance of +5.1% over the past month has outpaced the S&P 500 composite's +2.4% gain, but has lagged the +8.5% return of its Large Cap Pharmaceuticals industry peers. The company exhibits a strong forward-looking fundamental profile, with consensus estimates projecting significant growth. For the current quarter, EPS is expected to increase by 9% year-over-year to $3.27. More notably, full-year EPS is forecast to grow by 18.9% and 19.2% for the current and next fiscal years, respectively, supported by projected revenue increases of 7.6% and 9.2% for the same periods. This optimistic outlook is reinforced by a consistent history of execution, with AbbVie surpassing both revenue and EPS consensus estimates in each of the last four quarters. However, countervailing signals suggest a neutral near-term outlook. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the broader market. This is further substantiated by its valuation, which is graded 'C' and described as being at par with its peers, suggesting the strong growth prospects may already be reflected in the current share price.

Key Decisions for Investors

• Investors with a growth-oriented strategy may find AbbVie's projected double-digit earnings growth for the current and next fiscal year compelling, especially given its consistent track record of beating estimates.
• Considering the Zacks Rank #3 (Hold) and a valuation at par with peers, investors should be aware that the stock's near-term performance may be tethered to the broader market, as its strong fundamentals appear to be fully priced in.
• It is prudent to monitor sell-side earnings estimate revisions, as a positive shift in consensus could serve as a primary catalyst to upgrade the stock's rating and signal potential for market outperformance.